Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Argatroban (Exembol®) is recommended as an option for use within NHS Wales for anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy. The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment. |
|||
|
|||
Medicine details |
|||
| Medicine name | argatroban (Exembol®) | ||
| Formulation | 100 mg/ml concentrate for solution for infusion | ||
| Reference number | 1405 | ||
| Indication | Anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy. The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment |
||
| Company | Mitsubishi Tanabe Pharma Europe Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 4312 | ||
| NMG meeting date | 07/11/2012 | ||
| AWMSG meeting date | 12/12/2012 | ||
| Ratification by Welsh Government | 16/01/2013 | ||
| Date of issue | 23/01/2013 | ||
| Date of last review | August 2022 | ||
| Further information This appraisal recommendation was reviewed in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||